Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no single real-time mounjaro stock checker for the UK, and that trips up a lot of people. Mounjaro (tirzepatide) is a prescription-only medicine, so availability is managed through licensed pharmacies and their supply chains — not a public-facing tracker. What actually determines whether your dose is on the shelf, why certain strengths run short, and how a regulated pharmacy like ours approaches this is worth understanding before you start searching. The short version: checking availability and receiving treatment are the same step here, because a prescriber has to assess you first.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people search for a Mounjaro stock checker, they usually want a simple green/red dashboard. It is a reasonable thing to want. The reality is more layered. Mounjaro is a Prescription-Only Medicine regulated under the Human Medicines Regulations 2012, which means it can only be dispensed against a valid prescription, and the supply chain runs exclusively through MHRA-licensed wholesalers. No third-party site has live visibility into that chain.
What does exist is something more useful: GPhC-registered pharmacies can tell you, at the point of dispensing, exactly what they hold. At our current stock page we keep availability information as current as we can manage, but the definitive answer for your specific dose only comes once a prescriber has reviewed your case and confirmed the strength you need. That is not a bureaucratic hurdle; it is the reason the medicine is safe to use.
It is worth knowing that some third-party 'tracker' tools pull data from public sources rather than pharmacy systems, so they often lag by days or reflect national wholesale data rather than what any specific pharmacy actually holds. Treat them as rough signals, not live indicators.
A question our prescribers hear most weeks is why the higher doses seem harder to get. The pattern makes sense once you understand the titration schedule. Treatment starts at 2.5mg (a tolerability dose whose job is to let your system adjust) and steps upward through 5mg, 7.5mg, 10mg, 12.5mg and 15mg, typically in four-week intervals at the prescriber's direction. As the NHS rollout has expanded and private prescribing has grown, the volume of patients progressing to the upper strengths has increased sharply.
Eli Lilly has been scaling UK supply, but 10mg, 12.5mg and 15mg pens have seen the most disruption. If your specific strength is temporarily unavailable, the right move is to speak to your prescriber, not to skip a dose, take a double dose to compensate, or source a different strength informally. Our page on what to do when Mounjaro is out of stock covers that situation in detail. Separately, if you are wondering about building a buffer, the rules on how much you can hold at once are explained on our stocking-up page.
NICE's appraisal of tirzepatide (TA1026, published December 2024) recommends it for adults with a BMI of 35 or above alongside at least one weight-related condition. That formal recommendation brought a significant new wave of prescribing, which is the clearest single driver of recent supply pressure at the higher dose points.
Stock pressure creates a predictable problem. When the dose someone needs is temporarily unavailable from their usual source, the temptation is to search more broadly, and that is exactly when unverified sellers become dangerous. The MHRA has published warnings about counterfeit weight-loss pens sold through social media and unofficial websites; in October 2025 enforcement teams raided a site in Northampton producing fake tirzepatide pens. Some seized counterfeits have contained insulin rather than tirzepatide, a potentially life-threatening substitution. Sellers offering Mounjaro without a prescription, at prices far below market, or via social media channels are red flags, not solutions.
The right check is simple: any pharmacy supplying Mounjaro in the UK must be registered with the GPhC. You can verify our registration directly at the GPhC register (premises number 9012878). If a seller cannot point you to a verifiable GPhC registration, walk away. Our guide to buying Mounjaro online safely explains what to look for in more detail.
Cost is a factor here too. Since Eli Lilly's September 2025 price adjustment, private Mounjaro costs typically range from around £149 to £375 per month depending on dose and provider, as widely reported. Our Mounjaro price comparison page sets that in context, including what headline prices sometimes leave out, such as clinical review, prescription fees and aftercare. For context on buying genuine stock through the licensed supply chain, our stock and supply page has more detail.
At nume, every repeat order goes through a clinical review before it is dispensed, a named, GPhC-registered Independent Prescriber reads your information, not a piece of software. That review is also the point at which supply for your specific dose is confirmed. We source Mounjaro through the licensed UK supply chain, with authorised Eli Lilly supplier relationships, which gives us earlier visibility into allocation than informal channels.
If a specific strength is temporarily constrained, our prescribers can discuss your options, whether that is a brief wait, a clinical conversation about titration timing, or another path. That conversation cannot happen at a stock tracker; it happens in a consultation. If you are new to Mounjaro or considering a switch from another provider, the Mounjaro overview page covers eligibility, how the medicine works and what the clinical evidence shows. And if you are currently mid-treatment and wondering about your next pen, our 5mg availability page has current information for that dose specifically.
The NHS information on weight management injections is also a useful grounding if you want to understand how the broader prescribing landscape is shifting. Stock questions sit within a wider picture of demand, clinical oversight and supply, and navigating that picture with a regulated prescriber on your side is a different experience to refreshing a tracker alone. Patients travelling to the Canary Islands sometimes ask whether you can buy Mounjaro in Tenerife, and the answer involves important regulatory differences worth reading before you travel. Equally, if you are wondering whether a single consultation can cover multiple pens, our page on whether you can buy more than one Mounjaro pen at a time sets out exactly what the rules allow.
If you are ready to check your eligibility and confirm what is available for your dose, speak to our prescribers, the consultation is free, reviewed the same day, and there is no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.